Pancreatic Cancer Action Network Calls for Immediate, Sustained Investment in Research Toward Early Detection and Treatment ...

Because 13% survival is not enough, PanCAN has set a bold goal: Drive the five-year survival rate to 20% by 2030. We will do ...

To kick off 2026, PanCAN’s Volunteer Advisory Council shares a warm message of advice and encouragement with PanCAN ...

PanCAN board member Sharon Petry Bittman lost her husband to pancreatic cancer in 2018 and has been committed to raising ...

The PanCAN Patient Services team is here for patients and their loved ones as they navigate clinical trials. Our Case Managers offer personal, one-to-one support at every step of the search and ...

This Pancreatic Cancer Awareness Month, PanCAN is inviting you to shine a light on pancreatic cancer. Let’s uplift survivors and those living with the disease, honor the lives we’ve lost and help ...

Editor’s note: In this heartfelt interview, Jaylen Baron shares the story of her mother, Jane – an inspiring dance teacher, mentor and fighter – whose legacy is honored every year at PanCAN ...

Pancreatic Cancer Action Network Calls for Urgently Needed Research and Funding for Effective Early Detection Strategy and New Treatments for Patients LOS ANGELES, Calif. – (January 16, 2025) – After ...

Editor’s note: The “Research Spotlight” series is written by Dr. Anna Berkenblit, PanCAN’s Chief Scientific and Medical Officer. Each month, Dr. Berkenblit shares her insights into the latest news and ...

The U.S. Food and Drug Administration has granted accelerated approval for a new drug targeting a tumor alteration called NRG1 gene fusion found in roughly 3% of patients with pancreatic ...